Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-01-31
2006-01-31
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S210020, C514S002600, C536S017400, C540S200000, C562S575000, C562S560000, C562S561000, C562S557000, C562S562000, C562S570000, C562S571000, C562S573000, C562S559000, C562S445000, C562S567000, C562S444000, C548S535000, C548S496000
Reexamination Certificate
active
06992067
ABSTRACT:
Compounds of the formula I,in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.
REFERENCES:
patent: 5656624 (1997-08-01), Vaccaro et al.
patent: 5889002 (1999-03-01), Nielsen et al.
patent: 6225310 (2001-05-01), Nielsen et al.
patent: 6268343 (2001-07-01), Knudsen et al.
patent: WO 97/16455 (1997-05-01), None
patent: WO 97/26265 (1997-07-01), None
patent: WO 97/41097 (1997-11-01), None
patent: WO 97/45406 (1997-12-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 99/03861 (1999-01-01), None
patent: WO 00/63703 (2000-10-01), None
Castañer, R.M., et al., “Ezetimbe, Hypolipidemic Cholesterol Absorption Inhibitor SCH-58235,” Drugs of the Future 2000, 25(7):679-685.
Vaccaro, Wayne D., et al., “Sugar-Substituted 2-Azetidinone As Cholesterol Absorption Inhibitors,” Bioorganic & Medicinal Chemistry Letters 8(1998):35-40.
Vaccaro, Wayne D., et al., “Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar,” Bioorganic & Medicinal Chemistry Letters 8(1998):313-318.
van Heck, Margaret et.al., Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663, British Journal of Pharmacology 129:1748-1754 (2000).
Zaks, Aleksey, et al., Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH58235, Applied Biochemistry and Biotechnology, 73:205-213 (1998).
Flohr Stefanie
Frick Wendelin
Glombik Heiner
Heuer Hubert
Jaehne Gerhard
Aventis Pharma Deutschland GmbH
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Krishnan Ganapathy
Wilson James O.
LandOfFree
Diphenylazetidinones, process for their preparation,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diphenylazetidinones, process for their preparation,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diphenylazetidinones, process for their preparation,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3564098